Poseida Therapeutics

PSTX48

Penny Stock

$3.48arrow_drop_down3.60%-$0.13

Penny Stock

PSTX48

$3.48

arrow_drop_down3.60%-$0.13

Penny Stock

Performance History

Key Stats
Open	$3.61
Prev. Close	$3.61
EPS	-1.18
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$356.48M
PE Ratio	-

	LOW	HIGH
Day Range	3.31	3.61
52 Week Range	1.83	4.27

Ratios







EPS	-1.18

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Poseida Therapeutics (PSTX)

Poseida Therapeutics, Inc. (PSTX) is a biotechnology company focused on developing gene therapies to treat a wide range of diseases. The company's mission is to improve patient outcomes by delivering innovative, precision medicines. With a strong pipeline and a commitment to scientific excellence, Poseida is poised to make a significant impact in the field of gene therapy.

Poseida Therapeutics, Inc. has a market capitalization of XXXX and operates in the XXXX industry. The company's stock, PSTX, has a 52-week range of XXXX, indicating its stability and resilience in the market. The stock has recently gained attention from investors due to positive news and advancements in the development of its gene therapy platform.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Mark J. Gergen J.D.
Headquarters: San Diego
Employees: 348
Exchange: NASDAQ

Keep an eye on Poseida Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Poseida Therapeutics's (PSTX) price per share?

The current price per share for Poseida Therapeutics (PSTX) is $3.48. The stock has seen a price change of -$0.13 recently, indicating a -3.6% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Poseida Therapeutics (PSTX)?

For Poseida Therapeutics (PSTX), the 52-week high is $4.27, which is 22.7% from the current price. The 52-week low is $1.83, the current price is 90.16% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Poseida Therapeutics (PSTX) a growth stock?

Poseida Therapeutics (PSTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 15 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Poseida Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Poseida Therapeutics (PSTX) stock price performance year to date (YTD)?

As of the latest data, Poseida Therapeutics (PSTX) has a year-to-date price change of 2.96%. Over the past month, the stock has experienced a price change of 17.57%. Over the last three months, the change has been 31.32%. Over the past six months, the figure is 19.59%.

help

Is Poseida Therapeutics (PSTX) a profitable company?

Poseida Therapeutics (PSTX) has a net income of -$123.43M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 91.32% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -122.27% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $64.7M, although specific revenue growth data is currently not available. The gross profit is $59.09M. Operating income is noted at -$129.5M. Furthermore, the EBITDA is -$112.86M.

help

What is the market capitalization of Poseida Therapeutics (PSTX)?

Poseida Therapeutics (PSTX) has a market capitalization of $356.48M. The average daily trading volume is 434.65K, indicating the stock's liquidity and investor engagement.